|
Oct 9
|
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Aug 3
|
Verona Pharma plc's (NASDAQ:VRNA) Path To Profitability
|
|
Jul 30
|
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
|
|
Jul 25
|
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update
|
|
Jun 27
|
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
|
|
Jun 27
|
FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
|
|
Jun 26
|
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
|
|
Jun 13
|
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
|
May 10
|
Verona Pharma PLC Reports Q1 2024 Earnings: A Detailed Financial and Strategic Overview
|
|
May 10
|
Verona Pharma plc (NASDAQ:VRNA) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 9
|
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
|
|
May 2
|
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
|
|
Apr 25
|
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
|
|
Mar 4
|
Andrew Fisher Joins Verona Pharma as General Counsel
|
|
Mar 1
|
Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
|
|
Mar 1
|
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
|
|
Feb 29
|
Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 29
|
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Jan 15
|
Verona Pharma plc's (NASDAQ:VRNA) latest 11% decline adds to one-year losses, institutional investors may consider drastic measures
|